Like I’ve mentioned before, I tend not to trust
Post# of 148288
But he does make valid points about all aspects of CYDY, from management to leronlimab to financing. Combo is nearly a given and will eventually bring in revenue, as will Mono and the prostate test. It’s just a matter of time and more funding. Cancer is the lost promising and could bring in the largest increase in market value.